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succinylcholine chloride (2mg/kg) and themonkeyswere
ventilated with positive pressure 100% oxygen. Seizure
expression was monitored via scalp electroencephalog-
raphy (EEG), electromyography, and visuomotor mani-
festations in a nonparalyzed limb. One subject (No. 1)
had a chronically implanted intracerebral multicontact
electrode in place, permitting recording of intracerebral
EEG and TMS-induced voltage.5
The 2 trials with the commercial device did not pro-
duce a seizure. In contrast, each of the subsequent 8 trials
withthecustomdeviceproducedageneralizedtonic-clonic
seizure ranging in duration from 10 to 20 seconds, docu-
mentedbymotormanifestations, electromyography, scalp
EEG, and intracerebral EEG results. Intracerebral record-
ings documented that peak induced voltage with the cus-
tom TMS device matched that achieved with electrocon-
vulsive shock and occurred in the prefrontal cortex. The
commercially available device achieved less than half the
voltage induced by electroconvulsive shock.6
Magnetic seizure threshold was titrated by adminis-
tering trains of increasing durationuntil a generalized sei-
zurewas induced.Duetocoilheating,nomorethan2trains
could be administered in a single session. Thus, the vari-
oustraindurationswereadministeredacross4sessions.Sei-
zureswere reliably obtainedwith parameter settings of 40
Hz, 90% of maximal stimulator output, administered for
4 to 5 seconds. This represents stimulation at more than
400%of the electromyographically definedmotor thresh-
old. Stimulation at this intensity is far in excess of recom-
mended safety guidelines for humanuse of subconvulsive
rTMS.7 The purpose of this experiment, however, was in-
tentionalseizureinduction,andhighintensitieswereneeded
to overcome the anticonvulsant effects of anesthesia.
These findingsdemonstrate the feasibilityof rTMSsei-
zure induction under general anesthesia. The fact that the
commercial devicewas incapable of eliciting seizures sug-
gests that the broader pulsewidth and/or faster frequency
of the customdevicewere needed. Futureworkwill focus
onparameterizationandsafety tosupportclinicaluse inhu-
mans as a novel convulsive treatment. The enhanced con-
trol over dosage and focality achieved with rTMSmay of-
fer the capacity to focus seizure induction in the prefron-
tal cortex, thereby improving the efficacy and limiting the




convulsive rTMS, andmay provide a newmodel for stud-
ies of epilepsy.
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The Mood-Lowering Effect of Tryptophan
Depletion: Possible Explanation
for Discrepant Findings
T ryptophandepletion (TD) is an experimental pro-cedure for studying brain serotonin function. Themood-lowering effect of TD has been demon-
strated in formerly depressed patients treated with selec-
tive serotonin reuptake inhibitors (SSRIs) or monoamine
oxidase inhibitors1 and in medication-free women with a
history of recurrent depressive episodes.2 Typically, a little
more than half of the patients experience the effect. It is
not exactly clear why some patients experience the effect
while others do not. Several studies have recently found
that the effect may be less consistent than previously
thought. Moore et al3 observed no effect onmood in fully
remitted patients medicated with SSRIs. In a study4 of pa-
tients who had responded to treatment with citalopram,
only 5 of 12 patients relapsed, and the effect seemed to be
clinically significant in only 1 patient. In a third study,5
only 33% of 21 patients experienced a relapse. Moore et
al3 suggest that their unexpected finding may be related
to sample differences. In comparison with earlier studies,
their patients had been in treatment longer and were less
depressed. Therefore, the effect of TD may be limited to
recently recovered, medicated patients.3 However, clini-
cally significant symptom increases have been observed
in euthymic patients who had not been receiving medi-
cations for at least 6months.2 Another factor that might
be involved is a patient’s history of suicidal ideation.6
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A simple explanation for the negative findings may
be insufficient depletion. In Moore et al,3 the mean re-
duction of free plasma tryptophan levels was 52%. This
is lower than the typically reported 75% to 90% mean
reduction. However, because this value was signifi-
cantly different from the reduction in the placebo con-
dition (5.6%), the authors consider their study success-
ful in obtaining a contrast between TD and placebo
conditions. However, the extent of depletion needed to
achieve reliable mood effects has never been estab-
lished. It cannot be ruled out, therefore, that there is a
threshold that needs to be exceeded before an effect on
mood occurs. Some indirect evidence supports this hy-
pothesis. For instance, in the citalopram-responders
study,4 total plasma tryptophan reduction was alsomod-
est: 44.6% (free levels not reported). Furthermore, Del-
gado et al1 found a significant negative correlation
(r=−0.60) betweenminimum level of free tryptophan and
depression score. Inspection of their Figure 41(p 415) sug-
gests that a nonlinear relationship is also possible. Ten
of 12 patients with free tryptophan levels lower than or
equal to 1 μmol/L had a relapse, compared with only 2
of 9 patients with a level greater than 1 μmol/L. In the
study by Bremner et al,5 tryptophan reductions were not
statistically different between patients who relapsed and
those who did not. However, with the threshold hypoth-
esis in mind, the difference may be clinically significant.
The reduction in free plasma tryptophan in the relapse
group was 77.9%, compared with 57.5% in the no-
relapse group. Finally, a recent study found that a 67%
reduction of free tryptophan produced the expectedwors-
ening of depressive symptoms, whereas a 34% reduc-
tion did not.7 These studies5 suggest that the hypoth-
esized threshold lies somewhere around a 60% reduction
of free plasma tryptophan.7 However, it may be that the
hypothesized threshold should be defined in terms of the
ratio between tryptophan level and large neutral amino
acids (because these compete at the blood-brain barrier).
In conclusion, the effect of TD on mood in formerly de-
pressed patients may be more consistent than suggested
by these negative findings. A reanalysis of large datasets
may determine the relative contribution of extent of deple-
tion,medication status, presence of suicidal ideation, and
time since remission.
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In reply
Like many investigators, we have wondered why some but
not all euthymic depressed patients treated with SSRIs or
monoamine oxidase inhibitors (MAOIs) suffer a clinical re-
lapse following rapid tryptophan depletion (RTD). Many
clinical and behavioral measures vary widely between psy-
chiatric patients and healthy volunteers with RTD, al-
though plasma tryptophan reductions tend to be consistent
and robust in both groups. Numerous attempts to correlate
changes in plasma tryptophan scores with changes in de-
pression scores or other measures have often failed to indi-
cate a significant relationship.1-10
Dr Van der Does points out our lack of mood findings
and smaller plasma tryptophan depletions compared with
other reports.2,11 These findings may be attributable to our
depleting tryptophan in the afternoon and evening hours,
when plasma tryptophan levels tend to peak,12 and this may
have had a blunting effect on plasma tryptophan depletion.
However, even with these comparatively smaller deple-
tions, each of the 10 remitted depressed patients treated with
SSRIs showed significant effects on REM (rapid eye move-
ment) sleep measures following both strengths (25 g and 100
g) of a tryptophan-depleting mixture. Therefore, although
RTD did not induce depressive relapse in our patients, it did
have measurable central nervous system effects consistent
with depletion of serotonin. Similarly, in MAOI-treated de-
pressed patients, RTD reversed the MAOI-induced suppres-
sion of REM sleep without depressive relapse.13 Euthymic
patients receiving SSRIs or MAOIs are more vulnerable to
RTD-induced relapse early in treatment when they are in
partial remission (Hamilton Rating Scale for Depression
score, approximately 8-10 at 4-6 weeks) than later in treat-
ment when they are in full remission (Hamilton Rating Scale
for Depression score, approximately 3 at around 5 months).
How should depressive relapse be defined? According
to the criteria of Delgado et al,10 a 50% increase in Hamil-
ton Rating Scale for Depression score constitutes relapse.
Our remitted patients, for example, increased from 2 points
to 3 (a 50% increase) on a modified Hamilton Rating Scale
for Depression following RTD, but does this truly reflect clini-
cal relapse? In our studies of depressed patients and nor-
mal volunteers, RTD elicited changes such as increased Con-
fusion and decreased Vigor, Elation, and Friendliness in
Profile of Mood States subscales. Whether the gap between
these changes and depressive relapse is simply a matter of
degree remains to be seen. Based on the literature and our
own experience, we believe that true depressive relapse in-
duced by RTD in SSRI and MAOI euthymia needs to be veri-
fied by other groups.
In contrast to our REM sleep findings in SSRI and
MAOI-treated depressed patients, the RTD-induced REM
sleep effects are less consistent in healthy volunteers,1,2,14 de-
spite consistent depletion of plasma tryptophan. In our re-
examination of the data, the RTD-induced REM sleep mea-
sures in healthy volunteers show an almost dichotomous
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effect: either a very pronounced REM-disinhibiting effect (such
as an occurrence of sleep-onset REM) or virtually no effect.
In this regard, we agree with Dr Van der Does regarding
the notion of a “threshold” effect with RTD, but posit that it
is not based in plasma, but located more centrally, such as
in neuronal pools of serotonin.
P. J. Moore, PhD
J. C. Gillin, MD
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Did Samson Have Antisocial
Personality Disorder?
B esides intrinsic, historical, and literary interest,and pedagogical utility, the study of the historyof a disease can provide clues to its pathogen-
esis. It is necessary, but not sufficient, that the cause of
disease be at least as old as the disease itself. We note a
possible case of antisocial personality disorder (ASPD)
nearly 3000 years ago: the biblical figure Samson (Judges,1
chapters 13-16), son of Manoah.
The DSM-IV requires that 3 of 7 criteria be met for
the diagnosis of ASPD. Samson meets 6. (1) Failure to
conform to social norms with respect to lawful behav-
ior: The Philistines tried to arrest Samson after he
burned the Philistine fields (15:5) and went to Gaza
(16:1). (2) Deceitfulness, as indicated by repeated lying:
Samson did not tell his parents that he had killed a lion.
Furthermore, he proffered honey for his parents to eat,
but did not tell them it had come from the carcass of a
lion (14:9) and thus caused them to violate their dietary
laws. (3) Impulsivity: His burning of the Philistine
fields (15:5). (4) Irritability and aggressiveness: This is
indicated by his repeated involvement in physical
fights. (5) Reckless disregard for safety of self or oth-
ers: Samson is reported to have taken on and killed
1000 Philistines single-handedly (15:15). Telling
Delilah the secret to his strength (16:17), even after
she had attempted 3 times previously to get this secret,
can also be considered reckless disregard for safety of
self. (6) Lack of remorse: He gloated (15:16) after kill-
ing 1000 men.
In addition, Samson committed many of the ac-
tions listed in the criteria for conduct disorder—fire set-
ting, cruelty to small animals (15:5), bullying, initiating
physical fights, using a weapon (jawbone of ass) (15:
15), and stealing from a victim (14:19). If conduct dis-
order did not start when Samson was younger than 15
years, he was quite young (14:1-6).
Samson shows no evidence of schizophrenia. Some
of his behaviors (eg, not telling his parents that the honey
had been taken from a carcass) seem to have been done
during a nonmanic state.
Samson’s conduct was unacceptable in his time—
3000 Israelites (Samson’s own people!) captured Sam-
son and delivered him to the Philistines (15:12).
Recognition of the diagnosis of ASPD for Samson
may help in better understanding the biblical story,
and, in general, may help in instances when a leader has
ASPD. Also, we hope it stimulates interest in the history
of ASPD.
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